All Stories

  1. The Role of Non-Coding RNAs in Myelodysplastic Neoplasms
  2. Central Diabetes Insipidus in a Patient With Lymphoma: A Case Report
  3. Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications
  4. Unravelling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications
  5. Primary Bone Lymphoma: A Review of the Literature with Emphasis on Histopathology and Histogenesis
  6. Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews
  7. Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis
  8. Autophagy and cellular senescence in classical Hodgkin lymphoma
  9. Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia
  10. Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma
  11. CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome
  12. Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis
  13. Leishmaniasis mimicking multiple myeloma
  14. Novel Therapeutic Advances in β-Thalassemia
  15. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP
  16. Rifampicin-Induced Thrombocytopenia: A Case Report and Short Review of the Literature
  17. Real‐life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B‐cell lymphomas
  18. Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
  19. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies
  20. Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database
  21. Paraneoplastic Intrahepatic Cholestasis in Supradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated With Brentuximab Vedotin: A Case Report and Review of the Literature
  22. Hyponatremia in Patients with Hematologic Diseases
  23. Cyanosis Due to Methemoglobinemia as the Presenting Sign of Glucose-6-Phosphate Dehydrogenase Deficiency in a Child: Diagnostic and Clinical Implications
  24. Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
  25. The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas
  26. The effect of 5‐azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes
  27. Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry‐based cohort study
  28. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher‐risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes
  29. Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry
  30. Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective ...
  31. Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group
  32. A Novel εγδβ-Thalassemia Deletion Associated with Severe Anemia at Birth and a β-Thalassemia Intermedia Phenotype Later in Life in Three Generations of a Greek Family
  33. Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Regist...
  34. Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece
  35. The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome
  36. The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry
  37. Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry
  38. Chronic myelomonocytic leukemia treated with 5-azacytidine – results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system
  39. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group
  40. Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group
  41. Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival
  42. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis
  43. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group
  44. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival
  45. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies
  46. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation
  47. Sitosterolemia: A multifaceted metabolic disorder with important clinical consequences
  48. SLCO1B3 screening in colorectal cancer patients using High-Resolution Melting Analysis method and immunohistochemistry
  49. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
  50. Prognostic Factors for Immune Thrombocytopenia Outcome in Greek Children: A Retrospective Single-Centered Analysis
  51. Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review
  52. 2017 Clinical trials update in new treatments of β-thalassemia
  53. Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms
  54. Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment
  55. Megaloblastic anemia presenting with skin hyperpigmentation
  56. Rare variants in the spectrum of human herpesvirus 8/Epstein-Barr virus–copositive lymphoproliferations
  57. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs
  58. Direct Binding of Bcl-2 Family Proteins by Quercetin Triggers Its Pro-Apoptotic Activity
  59. Delta-Like Homologue 1 and Its Role in the Bone Marrow Niche and Hematologic Malignancies
  60. DLK1-DIO3 imprinted cluster in induced pluripotency: landscape in the mist
  61. Profile of pacritinib and its potential in the treatment of hematologic disorders
  62. A blood test to identify when melanoma metastasizes: a reality for melanoma management?
  63. How detection of epigenetic alterations of blood-borne DNA could improve melanoma diagnosis
  64. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma
  65. The human platelet: strong transcriptome correlations among individuals associate weakly with the platelet proteome
  66. Metronomic chemotherapy beyond misconceptions
  67. Polycomb group proteins and MYC: the cancer connection
  68. “Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group
  69. Adipocytokines are related to haemolytic and inflammatory biomarkers in sickle cell beta thalassaemia
  70. Revisiting bleomycin from pathophysiology to safe clinical use
  71. Methylated Tissue Factor Pathway Inhibitor 2 (TFPI2) DNA in Serum Is a Biomarker of Metastatic Melanoma
  72. Cancer Epigenetics: New Therapies and New Challenges
  73. Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma
  74. Clinical trial design in biosimilar drug development
  75. Non‐coding RNAs and EZH2 interactions in cancer: Long and short tales from the transcriptome
  76. The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma
  77. The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis
  78. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis
  79. Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era
  80. NT5E CpG island methylation is a favourable breast cancer biomarker
  81. Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients
  82. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity
  83. Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications
  84. Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in cancer
  85. Targeting Oncogenic Protein-Protein Interactions by Diversity Oriented Synthesis and Combinatorial Chemistry Approaches
  86. MEG3 imprinted gene contribution in tumorigenesis
  87. Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer
  88. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions
  89. Study of specific genetic and epigenetic variables in multiple myeloma
  90. Cytokine and Adhesion Molecule Expression Evolves Between the Neutrophilic and Lymphocytic Phases of Viral Meningitis
  91. Hematopoietic stem cell transplantation
  92. DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt's lymphoma
  93. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes
  94. Serum Adipocytokine and Vascular Inflammation Marker Levels in Beta-Thalassaemia Major Patients
  95. The prolyl‐hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia
  96. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion
  97. Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia
  98. von Hippel–Lindau Methylation Status in Patients with Multiple Myeloma: A Potential Predictive Factor for the Development of Bone Disease
  99. P027 Prognostic significance of less frequent or rare chromosome abnormalities in Greek patients with myelodysplastic syndromes
  100. P113 Treatment with lenalidomide for patients with myelodysplastic syndromes (MDS): report of the Hellenic experience on 73 patients. A retrospective analysis of the Hellenic MDS Study Group
  101. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease
  102. Methylation Changes in Neoplasia
  103. Promoter Hypermethylation of the MEG3 (DLK1/MEG3) Imprinted Gene in Multiple Myeloma
  104. The absence of CDKN1C (p57KIP2) promoter methylation in myeloid malignancies also characterizes plasma cell neoplasms
  105. Methylation analysis of the von Hippel-Lindau gene in acute myeloid leukaemia and myelodysplastic syndromes
  106. Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases
  107. Cryptococcus lung infection complicating fludarabine treatment in a chronic lymphocytic leukemia patient
  108. Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support
  109. The genomics of new drugs in sickle cell disease
  110. The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma
  111. C-Reactive Protein and Vascular Cell Adhesion Molecule-1 as Markers of Severity in Sickle Cell Disease
  112. Host Pharmacogenetics in the Treatment of HIV and Cancer
  113. The Rationale and Development of New Drugs to Treat HIV Infection
  114. Serum levels of soluble interleukin-2 receptor alpha (sIL-2Rα) as a predictor of outcome in brucellosis
  115. Serum interleukin (IL)‐1, IL‐2, sIL‐2Ra, IL‐6 and thrombopoietin levels in patients with chronic myeloproliferative diseases
  116. Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients
  117. Treatment of β-Thalassemia Patients with Recombinant Human Erythropoietin: Effect on Transfusion Requirements and Soluble Adhesion Molecules
  118. Recombinant human erythropoietin therapy in a transfusion-dependent β-thalassemia major patient
  119. Treatment of plasma cell leukemia with vincristine, liposomal doxorubicin and dexamethasone
  120. Investigation for the presence of anti‐erythropoietin antibodies in patients with myelodysplastic syndromes
  121. Serum levels of IL‐6 and its soluble receptor (sIL‐6R) in Waldenström's macroglobulinemia
  122. The role of cytokines in sickle cell disease
  123. Prolonged interferon‐alpha‐2b treatment of hairy cell leukemia patients
  124. Alpha-2-Macroglobulin and Interleukin-6 Levels in Steady-State Sickle Cell Disease Patients
  125. Serum beta‐2‐microglobulin, TNF‐α and interleukins in myeloproliferative disorders
  126. Combination therapy with interferon-alpha-2b and hydroxyurea in patients with chronic myelogenous leukemia
  127. A Patient with Multiple Myeloma, Amyloidosis and Light-Chain Deposition Disease in Kidneys with a Long Survival